Author Topic: Where does Vigora 100 fit into the treatment of pulmonary arterial hypertension?  (Read 125 times)


  • Newbie
  • *
  • Posts: 1
    • View Profile
Vigora 100 mg (sildenafil citrate) is primarily used for the treatment of erectile dysfunction (ED) in men. It works by relaxing blood vessels in the penis, allowing blood to flow into the penis when sexually aroused, thus helping to achieve and maintain an erection. Pulmonary arterial hypertension (PAH), on the other hand, is a condition characterized by high blood pressure in the arteries of the lungs. PAH requires specific medications that target the pulmonary circulation to reduce blood pressure and improve symptoms. Vigora 100 mg commonly used for PAH belong to classes such as prostacyclins, endothelin receptor antagonists, and phosphodiesterase-5 (PDE-5) inhibitors. While sildenafil (the active ingredient in Vigora 100 mg) is a PDE-5 inhibitor and is used for PAH under different brand names (like Revatio), the dosage and usage are typically different from those used for erectile dysfunction. In PAH, sildenafil is used at lower doses and with a different dosing schedule compared to its use for ED. Therefore, Vigora 100 mg is not directly used for the treatment of PAH as it is typically prescribed for erectile dysfunction. For PAH treatment, healthcare providers would prescribe sildenafil at a different dose and under a different brand name (Revatio) tailored specifically for that condition.